The correlation between expression of sip protein in different serotypes of group b streptococcus and diagnosis

Cheng, Shiliang; Han, Ji-Ae; Huang, Yue; Yan, Qin; Lǚ, Gang; Yuan, Zihao; Huang, Guanjun; Zheng, Jian; Liu, Tianqiang

doi:10.1016/j.heliyon.2019.e01899

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The obtained results indicated relatively higher sensitivity in comparison with mono-antigen fusion protein Sip [52]. Immunogenicity of the Sip protein, according to its conservation, was also investigated in the context of usage for monoclonal antibody generation to develop immunochromatographic test kit for GBS detection in pregnant women [53]. Another study was focused on examination of Sip protein as a biomarker in a rapid immunochromatographic test for detection of Group B streptococcus colonization in vaginal and/or rectal tracts in pregnant women during the 35th-37th weeks of pregnancy.…”

Section: Sip Proteinmentioning

confidence: 99%

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Dobrut

Brzychczy-Włoch

2021

Pathogens

View full text Add to dashboard Cite

Streptococcus agalactiae (Group B Streptococcus, GBS) is an opportunistic pathogen, which asymptomatically colonizes the gastrointestinal and genitourinary tract of up to one third of healthy adults. Nevertheless, GBS carriage in pregnant women may lead to several health issues in newborns causing life threatening infection, such as sepsis, pneumonia or meningitis. Recommended GBS screening in pregnant women significantly reduced morbidity and mortality in infants. Nevertheless, intrapartum antibiotic prophylaxis, recommended following the detection of carriage or in case of lack of a carriage test result for pregnant women who demonstrate certain risk factors, led to the expansion of the adverse phenomenon of bacterial resistance to antibiotics. In our paper, we reviewed some immunogenic GBS proteins, i.e., Alp family proteins, β protein, Lmb, Sip, BibA, FsbA, ScpB, enolase, elongation factor Tu, IMPDH, and GroEL, which possess features characteristic of good candidates for immunodiagnostic assays for GBS carriage detection, such as immunoreactivity and specificity. We assume that they can be used as an alternative diagnostic method to the presently recommended bacteriological cultivation and MALDI.

show abstract

Section: Sip Proteinmentioning

confidence: 99%

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Dobrut

Brzychczy-Włoch

2021

Pathogens

View full text Add to dashboard Cite

show abstract

“…The surface immunogenic protein (Sip) was initially identified and named by Brodeur et al in 2000 through immunological screening [ 61 ]. This 45 kDa surface-localized protein is present in GBS serotypes, Ia, Ib, and II-IX, and the sequence of the sip gene is highly conserved in different isolates [ 60 , 62 ]. Animal experiments demonstrated that Sip effectively protected mice from lethal infection with five serotypes of Streptococcus agalactiae [ 61 , 63 ].…”

Section: Discussionmentioning

confidence: 99%

Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines

Duan,

Huang,

et al. 2024

Vaccines

View full text Add to dashboard Cite

Group B Streptococcus (GBS) is a life-threatening opportunistic pathogen, particularly in pregnant women, infants, and the elderly. Currently, maternal vaccination is considered the most viable long-term option for preventing GBS mother-to-infant infection, and two polysaccharide conjugate vaccines utilizing CRM197 as a carrier protein have undergone clinical phase II trials. Surface immunogenic protein (Sip), present in all identified serotypes of GBS strains so far, is a protective surface protein of GBS. In this study, the type Ia capsular polysaccharide (CPS) of GBS was utilized as a model to develop candidate antigens for a polysaccharide conjugate vaccine by coupling it with the Sip of GBS and the traditional carrier protein CRM197. Serum analysis from immunized New Zealand rabbits and CD1 mice revealed that there was no significant difference in antibody titers between the Ia-Sip group and Ia-CRM197 group; however, both were significantly higher than those observed in the Ia polysaccharide group. Opsonophagocytosis and passive immune protection results using rabbit serum indicated no significant difference between the Ia-Sip and Ia-CRM197 groups, both outperforming the Ia polysaccharide group. Furthermore, serum from the Ia-Sip group had a cross-protective effect on multiple types of GBS strains. The challenge test results in CD1 mice demonstrated that the Ia-Sip group provided complete protection against lethal doses of bacteria and also showed cross-protection against type III strain. Our study demonstrates for the first time that Ia-Sip is immunogenic and provides serotype-independent protection in glycan conjugate vaccines, which also indicates Sip may serve as an excellent carrier protein for GBS glycan conjugate vaccines and provide cross-protection against multiple GBS strains.

show abstract

Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis

Gent,

Lu,

Lukhele

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Group B Streptococcus (GBS) is a major cause of pneumonia, sepsis, and meningitis in infants younger than 3 months of age. Furthermore, GBS infection in pregnant women is associated with stillbirths and pre-term delivery. It also causes disease in immunocompromised adults and the elderly, but the highest incidence of the disease occurs in neonates and young infants. At this time, there are no licensed vaccines against GBS. Complete GBS genome sequencing has helped identify genetically conserved and immunogenic proteins, which could serve as vaccine immunogens. In this study, in silico reverse vaccinology method were used to evaluate the prevalence and conservation of GBS proteins in invasive and colonizing isolates from South African infants and women, respectively. Furthermore, this study aimed to predict potential GBS vaccine targets by evaluating metrics such as antigenicity, physico-chemical properties, subcellular localization, secondary and tertiary structures, and epitope prediction and conservation. A total of 648 invasive and 603 colonizing GBS isolate sequences were screened against a panel of 89 candidate GBS proteins. Ten of the 89 proteins were highly genetically conserved in invasive and colonizing GBS isolates, nine of which were computationally inferred proteins (gbs2106, SAN_1577, SAN_0356, SAN_1808, SAN_1685, SAN_0413, SAN_0990, SAN_1040, SAN_0226) and one was the surface Immunogenic Protein (SIP). Additionally, the nine proteins were predicted to be more antigenic than the SIP protein (antigenicity score of > 0.6498), highlighting their potential as GBS vaccine antigen targets. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-024-73175-4.

show abstract

The correlation between expression of sip protein in different serotypes of group b streptococcus and diagnosis

Cited by 3 publications

References 9 publications

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Immunogenic Proteins of Group B Streptococcus—Potential Antigens in Immunodiagnostic Assay for GBS Detection

Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines

Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis

Contact Info

Product

Resources

About